Radiation Therapy Without Hormone Therapy for Women Age 70 or Above with Low-Risk Early Breast Cancer: A Microsimulation.


Journal

International journal of radiation oncology, biology, physics
ISSN: 1879-355X
Titre abrégé: Int J Radiat Oncol Biol Phys
Pays: United States
ID NLM: 7603616

Informations de publication

Date de publication:
01 10 2019
Historique:
received: 11 04 2019
revised: 04 06 2019
accepted: 08 06 2019
pubmed: 19 6 2019
medline: 28 1 2020
entrez: 19 6 2019
Statut: ppublish

Résumé

Hormone therapy without radiation therapy is considered appropriate for women age 70 or above with low-risk, hormone-positive breast cancer after partial mastectomy. However, some patients may prefer radiation without hormone therapy, for which there is minimal modern data. We modeled the comparative efficacy of aromatase inhibition alone without radiation versus radiation alone without hormone therapy. We constructed a patient-level Markov model and compared 5 years of anastrozole to a 15-fraction course of radiation without boost or anastrozole. The relative effectiveness between treatments was based on the National Surgical Adjuvant Breast and Bowel Project B-21 trial, which was further adjusted such that the endocrine-alone arm matched the Cancer and Leukemia Group B 9343 and PRIME II trials. Common or severe side effects were considered. Eight survival metrics were assessed and validated against clinical trial data. The cost-efficacy of each strategy was considered using the quality-adjusted life year and incremental cost-effectiveness ratio (ICER). The model's predicted outcomes matched those demonstrated by modern trials. Aromatase inhibitors were superior in preventing contralateral cancers, with a small impact on the risk of distant metastatic disease. Radiation was superior in preventing ipsilateral breast tumor recurrence with a small impact on regional failure. No clinically significant differences were seen in the other 4 oncologic endpoints. Differences in quality-adjusted life years were small, but radiation therapy was $3809 more expensive over the average lifetime. The ICER suggested anastrozole was cost-effective in 62% of probabilistic simulations. However, the ICER was unstable owing to a denominator that approached zero. Women age 70 or above with low-risk early breast cancer who are reluctant or unable to pursue adjuvant aromatase inhibition can safely pursue adjuvant radiation alone with limited differences in outcome and a modest increase in costs.

Identifiants

pubmed: 31212043
pii: S0360-3016(19)30849-1
doi: 10.1016/j.ijrobp.2019.06.014
pii:
doi:

Substances chimiques

Antineoplastic Agents, Hormonal 0
Aromatase Inhibitors 0
Receptors, Estrogen 0
Anastrozole 2Z07MYW1AZ

Types de publication

Comparative Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

296-306

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

Matthew C Ward (MC)

Levine Cancer Institute, Atrium Health, Charlotte, North Carolina.

Frank Vicini (F)

21st Century Oncology, Farmington Hills, Michigan.

Manjeet Chadha (M)

Ichan School of Medicine at Mt. Sinai, New York City, New York.

Lori Pierce (L)

University of Michigan, Ann Arbor, Michigan.

Abram Recht (A)

Beth Israel Deaconess Medical Center, Boston, Massachusetts.

James Hayman (J)

University of Michigan, Ann Arbor, Michigan.

Nikhil G Thaker (NG)

Arizona Oncology, Tucson, Arizona.

Atif Khan (A)

Memorial Sloan Kettering Cancer Center, New York City, New York.

Martin Keisch (M)

Cancer HealthCare Associates, Miami, Florida.

Chirag Shah (C)

Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio. Electronic address: shahc4@ccf.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH